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Abstract
Introduction: Colorectal cancer (CRC) is a common but largely preventable disease with suboptimal screening rates
despite national guidelines to screen individuals age 50–75. Single-component interventions aimed to improve
screening uptake only modestly improve rates; data suggest that multi-modal approaches may be more effective.
Methods: We designed, implemented, and evaluated the impact of a multi-modal intervention on CRC screening
uptake among unscreened patients in a large managed care population. Patient-level components included a mailed
letter with education about screening options and pre-colonoscopy telephone counseling. For providers, we
facilitated communication of screening test results and work-flow for abnormal results. System-level modifications
included establishment of a patient navigator, expedited work-up for abnormal results, and stream-lined colonoscopy
scheduling. We measured the rate of screening uptake overall, screening uptake by modality, change in the
proportion of the population screened, and positive fecal immunochemical test (FIT) follow-up rates in the 1-year
study period.
Results: There were 5093 patients in the intervention cohort. Of these, 33.2% participated in FIT or colonoscopy
screening within 1 year of the mailing. A total of 1078 (21.2%) participants completed a FIT and 611 (12.0%) completed
a screening colonoscopy. The screening rate in the managed care population increased from 65.1 to 76.6%. Fifty-nine
patients (5.5%) had a positive FIT, of which 30 (50.8%) completed a diagnostic colonoscopy.
Conclusion: Multi-modal interventions can result in substantial improvement in CRC screening uptake in large and
diverse managed care populations.
Translational Impact: Health systems should shift their focus from single-level to multi-level interventions when
addressing barriers to CRC screening.
Introduction
In the United States, colorectal cancer (CRC) is the
third most commonly diagnosed cancer and the second
most common cause of cancer-related mortality in men
and women1–4. Incidence and mortality have declined
over the past 2 decades, largely due to substantial national
public health and screening efforts1,2. However, screening
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uptake remains subpar. Currently, only 65% of eligible
adults aged 50–75 years are screened5, far below the
National Colorectal Cancer Roundtable (NCCRT) goal to
screen 80% of Americans by 2018.
The United States Preventive Services Task Force
(USPSTF) reaffirmed the importance of screening
average-risk Americans aged 50 to 75 in their 2016
updated CRC screening guidelines6. Given the lack of
comparative effectiveness studies demonstrating super-
iority of any single screening strategy, the USPSTF high-
lighted the importance of maximizing adherence to
screening and implied a strong role for patient preference
in screening method utilization. More recently, the Multi-
Society Task Force (MSTF) guidelines recommended
fecal immunochemical test (FIT) and colonoscopy as first-
tier screening tests, again emphasizing the importance of
offering FIT in screening programs7. Overall, these
guidelines are encouraging for health systems that offer
low-cost and convenient modalities like FIT in addition to
colonoscopy for screening8.
Achieving a high CRC screening rate can be challenging
in large health systems and health maintenance organi-
zations (HMOs) with diverse patient populations and
large provider groups. Screening rates are as low as 26% in
such settings and rarely reach rates over 69% without
significant system supports9–11. Single-component inter-
ventions aimed to improve CRC screening uptake in
integrated health systems have included changes to health
plan policies and practices12, enhanced patient-test
interaction13–16, FIT mailings programs10,17,18, reminder
systems19, financial incentives20, and use of patient navi-
gators11. While many of these efforts have shown some
success in augmenting screening rates, none have raised
rates over 80%, and most leave multiple mutable barriers
to screening unaddressed.
Multi-modal interventions aimed to increase uptake of
CRC screening via integrated patient-, provider-, and
system-level components may be more effective; however,
prospective data examining their impact in managed care
settings is limited13,21. Florea et al.22 evaluated a multi-
modal intervention to increase CRC screening uptake in
three federally qualified health centers serving a pre-
dominantly low income and underinsured population.
Their intervention incorporating staff and provider edu-
cation, patient decision aids and an electronic medical
record (EMR)-based reminder system led to 6.3–6.9%
increases in CRC screening uptake. Faced with suboptimal
CRC screening rates among managed care patients in our
academic health center, we began a multi-disciplinary
quality improvement (QI) initiative. Led by leadership in
both internal medicine and gastroenterology (GI), our
initiative aimed to develop and evaluate the impact of a
multi-component intervention on CRC screening rates in
our population of unscreened managed care patients.
Methods
Setting and population
In 2014, the UCLA Medical Group, a risk-bearing
organizational unit of UCLA Health, collaborated with the
UCLA GI QI team to design a CRC screening initiative for
the managed care population. UCLA Health is a large
academic medical center with defined primary care
populations and robust referral-based care. The primary
care population is defined by patients enrolled in risk-
based commercial HMO contracts that receive coverage
for care services only via UCLA Medical Group as part of
the California delegated model. The population includes
60,000 patients with a baseline CRC screening rate of
65.1% in those eligible for CRC screening. The aim of this
QI was to increase CRC screening uptake in this patient
population.
With assistance from a data analyst from the UCLA
Value Analytics (VA) team, we used EMR, billings data,
and claims data to identify the cohort of managed care
patients due for CRC screening. We targeted patients
within the managed care population aged 51 to 75 who
were not up-to-date with screening, defined by a lack of
FIT or fecal occult blood testing (FOBT) in the past year,
flexible sigmoidoscopy in the past 5 years, or colonoscopy
in the past 10 years, consistent with NCQA Healthcare
Effectiveness Data and Information Set (HEDIS) specifi-
cations23. Patients also required a valid mailing address to
be included. Exclusion criteria included a personal history
of CRC and prior total colectomy.
Overview of intervention and implementation
We evaluated the impact of the multi-component
intervention on CRC screening rates. The intervention
included patient-level, provider-level, and system-level
features. All components were initiated simultaneously
and were based on programs previously demonstrated to
increase CRC screening rates in similar settings10,11,17,18
or tailored to address specific barriers at our institution
(Table 1). We then evaluated the screening uptake by FIT
and by colonoscopy after QI implementation. The UCLA
institutional review board deemed our work exempt sys-
tems improvement consistent with ongoing hospital QI
efforts.
Patient-level interventions
Each eligible patient received one or two mailed letters
between June 2015 and October 2015 with an enclosed
FIT kit. The first wave of letters was sent to patients who
met eligibility criteria on 16 June, 2015. A second wave of
identical letters was sent to patients that had not com-
pleted screening in the 4-month time interval after the
initial mailing and to a small group of managed care
patients newly eligible for screening on 16 October, 2015.
The letter informed patients of the national CRC
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screening recommendation and described both FIT and
colonoscopy screening. FIT kits were OC-Auto FIT-
CHEK kits made by Polymedco, Inc. and contained a self-
addressed mailer and postage for the UCLA laboratory.
Patients were asked in the letter to either complete the
FIT kit or to call and schedule an appointment with their
primary care provider (PCP) to discuss colonoscopy and
alternative forms of screening. Patients were also provided
a form to submit information about screening performed
outside UCLA Health.
Patients with positive FITs were informed by their
PCPs. A patient navigator then worked alongside GI
schedulers to contact the patient to schedule the colo-
noscopy and provide peri-colonoscopy instructions. Our
patient navigator was a registered nurse with interactive
telephone counseling training on how to provide diet,
bowel preparation, and medication management for
colonoscopy. The patient navigator also served as a liaison
between schedulers and patients when scheduling
screening colonoscopies through the open-access endo-
scopy facility.
Provider-level interventions
Provider-level components included education about
the CRC screening program and improved communica-
tion between GI and primary care teams regarding
positive FIT results. We informed PCPs about the plan-
ned QI to increase CRC screening rates through email
notifications. When a FIT was negative, the patient’s PCP
received an EMR inbox message to review results and
enter updated screening data into the Health Main-
tenance (HM) tab. The HM tab is an electronic portal
within each patient’s EMR chart where providers can
view, enter, and reference the status of preventive mea-
sures like cancer screening for individual patients.
For all positive FIT results, PCPs received a personalized
email generated by a member of the QI team informing
them of the positive result and offering assistance with
coordination of a diagnostic colonoscopy. PCPs were
asked to verify that colonoscopy was appropriate and, if
so, to place an electronic request for one. Our patient
navigator then contacted the patient to schedule the
procedure as described above. Endoscopists completed
diagnostic colonoscopies, reviewed pathology results to
determine surveillance colonoscopy intervals, commu-
nicated results to patients via phone or mailed letters and
entered colonoscopy results and surveillance recommen-
dations into the HM tab. For patients with findings con-
cerning for malignancy, endoscopists ordered appropriate
cross-sectional imaging and referrals to colorectal surgery
and oncology.
System-level interventions
System-level interventions included coordination of
care processes among our QI team, PCPs, the GI division,
and the scheduling department to achieve diagnostic
colonoscopies for FIT-positive patients. Once the PCP
placed an electronic request for a diagnostic colonoscopy,
the procedure was scheduled by GI scheduling. If the
patient could not be reached, the scheduler left a voice
message prompting patients to call back. If a call back was
not received, additional efforts included a second phone
call and an electronic message to the PCP to re-refer the
patient for colonoscopy when appropriate. Diagnostic
colonoscopies were prioritized for completion within
6 months. The GI QI team verified all screening results
and surveillance intervals and entered any missing data.
Statistical analysis
Our primary outcomes of interest were the rate of
screening uptake after the intervention and the change in
the proportion of the managed care population screened
after the intervention. For all analyses, we excluded
patients who reported up-to-date screening. Screening
uptake was measured at 30-day intervals and at 1 year
after receipt of the first mailed FIT kit. We calculated the
pre-intervention screening rate as the percentage of
screening-eligible patients in the managed care popula-
tion that were up-to-date with screening on 16 June, 2015
where the denominator was the total number of managed
care patients eligible for CRC screening, and the
numerator was the number of these patients that met
Table 1 Intervention components to improve colorectal cancer (CRC) screening uptake
Patient-level components Provider-level components System-level components
Mailed CRC education and FIT kit Notification of QI goals Stream-lined work-flow for abnormal screening
test results
Introduction of patient navigator with interactive
telephone counseling
Enhanced communication of screening
results
Improved process for colonoscopy scheduling
Improved work-flow for abnormal FIT
results
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HEDIS screening requirements. Post-intervention
screening rates were calculated at 30, 60, 90, 180, 270,
and 365 days after the start of the intervention.
Additionally, we examined screening uptake and
method of screening used by age, sex, race, and ethnicity.
We used one mutually-exclusive variable that combined
concepts of race and ethnicity by including Hispanic as a
primary race (non-Hispanic white, non-Hispanic black,
Hispanic, Asian, other). For patients with a positive FIT,
we examined the rate of and time to diagnostic colono-
scopy. Finally, we investigated screening and diagnostic
colonoscopy findings.
Results
Descriptive characteristics and screening uptake
Intervention letters were mailed to 5186 patients. There
were 93 patients that reported up-to-date screening,
leaving 5093 patients in the final intervention cohort
(Fig. 1). The cohort was 55.5% female, 50.3% white, 7.9%
black, 12.4% Hispanic, 10.1% Asian, and 5.8% other race/
ethnicity. The mean age was 61.1 years (Table 2).
Overall, 33.2% of patients participated in FIT (21.2%) or
colonoscopy (12.0%) screening within 1 year of the mailed
letter screening. The CRC screening rate for the screen-
eligible managed care population was 65.1% prior to the
start of the intervention and increased to 76.6% after the
1-year study period. Screening rates at 30-day intervals
are provided in Fig. 2. The percent of patients screened
increased for each 30-day interval from 3.2% at
30 days to 33.2% at 1 year. Screening uptake was higher in
women than in men (34.6% vs. 31.4%, p= 0.02)
and higher in Asians than in whites (45.6% vs. 33.8%,
p < 0.001).
Screening uptake by modality and screening colonoscopy
findings
FIT was the most common screening modality (1078,
63.8%). Of those screened, 611 (36.2%) patients arranged
colonoscopic screening (Table 2). Among whites who
participated in screening, 63.3% completed FIT and 36.7%
completed colonoscopy. FIT rates were 59.2% for blacks,
62.7% for Hispanics, and 61.7% for Asians screened.
(Table 2). Among those who utilized FIT, FIT was most
often completed within 30 to 60 days of the initial mailing
or not completed at all (Fig. 2).
For patients who underwent screening colonoscopy, 158
(25.9%) had non-advanced adenomas, 36 (5.9%) had
advanced tubular adenomas and 6 (1.0%) had colon or
rectal adenocarcinomas. The remaining colonoscopies
had poor preparation (11 patients, 1.8%) and normal or
other findings such as internal hemorrhoids or colitis
(400 patients, 65.5%).
Fig. 1 Intervention cohort by study inclusion and exclusion criteria
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Screening uptake by number of mailings
According to the intervention design, 1701 patients
received one mailing while 3485 patients received two.
The overall screening uptake at the end of 1 year was
67.8% for patients that received one letter and 16.9% for
patients that received two letters. Among those that
received one letter and completed screening, 73.2% were
screened by FIT. Among those screened that received two
letters, 46.2% were screened by FIT.
Follow-up after positive FIT and diagnostic colonoscopy
results
There were 59 (5.5%) patients with positive FIT
results. Of these, a total of 10 (16.9%), 23 (39.0%), and
30 (50.8%) completed a diagnostic colonoscopy within
90, 180, and 365 days, respectively (Fig. 3). At the end of
the 1-year period, 29 (49.2%) participants had not
completed a diagnostic colonoscopy after a positive
FIT.
Table 2 Demographic characteristics of the intervention cohort and overall CRC screening uptake at 1 year, N= 5093
Total N (%) or mean (s.d.) N (%) screened (FIT or colonoscopy) N (%) screened by FIT N (%) screened by colonoscopy
Age 61.1 ( ± 7.5) 62.1 ( ± 7.6) 63.1 ( ± 7.5) 60.2 ( ± 7.3)
Sex
Male 2266 (44.5) 712 (31.4) 442 (62.1) 270 (37.9)
Female 2827 (55.5) 977 (34.6)a 636 (65.1) 341 (34.9)
Race/ethnicity
White 2562 (50.3) 866 (33.8) 548 (63.3) 318 (36.7)
Black 403 (7.9) 142 (35.2) 84 (59.2) 58 (40.8)
Hispanic 632 (12.4) 228 (36.1) 143 (62.7) 85 (37.3)
Asian 515 (10.1) 235 (45.6)b 145 (61.7) 90 (38.3)
Other 296 (5.8) 103 (34.8) 69 (67.0) 34 (33.0)
Unknown 685 (13.5) 115 (16.8)b 89 (77.4)b 26 (22.6)b
Total 5093 1689 (33.2) 1078 (63.8) 611 (36.2)
CRC colorectal cancer, FIT fecal immunochemical test, s.d. standard deviation
aSignifies significant difference in screening rate between males and females at p < 0.05
bSignifies significant difference in screening rate from whites at p < 0.05
Fig. 2 Colorectal cancer (CRC) screening uptake within intervention cohort at 30 days, 60 days, 90 days, 180 days, 270 days, and 365 days; N (%)
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Results from diagnostic colonoscopies were as follows: 9
patients (30.0%) had non-advanced adenomas, 3 (10.0%)
had advanced tubular adenomas, and 2 (6.7%) had a colon
or rectal adenocarcinoma. Fifteen colonoscopies were
normal (50.0%), and one case (3.3%) had poor
preparation.
Discussion
We implemented a multi-modal intervention to
increase CRC screening rates among managed care
patients in a large university-affiliated health system and
observed a screening participation rate of 33.2% and a
screening rate increase from 65.1% to 76.6%. The overall
screening rate of 76.6% nears the NCCRT goal of 80% and
is comparable to rates in other large integrated health
systems with managed care populations such as Kaiser
Permanente8,24. Additionally, our findings are consistent
with a similar multi-level QI initiative that resulted in
23.6% screening uptake22. We hypothesize that our
screening uptake rate was higher due to additional
intervention components. Screening uptake rates in our
HMO population were significantly higher in women
compared to men and in Asians compared to whites. The
FIT-positive rate of approximately 5% seen among our
patients is comparable to other FIT mailing programs
nationally8,25.
FIT screening occurred most often within the first 30 to
60 days of the initial mailing and declined thereafter,
suggesting that patients’ willingness to participate in
screening attenuates over time. We also noted that
approximately 17% of patients required two mailings to
comply with screening, supporting the use of serial out-
reach attempts. Colonoscopic screening most commonly
occurred 90–180 days from the initial mailing, a delay
likely explained by procedure scheduling logistics and
wait-times.
Approximately half of the patients with positive
FITs did not undergo diagnostic colonoscopy within
1 year, a finding consistent with prior studies that suggest
a 40–60% colonoscopy follow-up rate after a positive
FIT26–31. Of note, two positive FIT patients were deemed
too ill to undergo colonoscopy and alternatively had CT
colonography. Nonetheless, these findings suggest a need
for further investigation into why rates of colonoscopic
follow-up after positive FIT are low and for interventions
to improve follow-up rates.
Several factors likely contributed to high screening
uptake in our managed care cohort. Patients had a choice
between two screening modalities, and data support that
screening uptake is highest when patients are offered two
or more screening modalities32. Our intervention also
included several opportunities for contact with patients
through repeated mailings and the use of a patient navi-
gator. Prior studies demonstrated that direct mailing with
follow-up reminders had a significant impact on increas-
ing CRC screening rates33,34. Third, our intervention
employed a patient navigator. Current peer-reviewed
literature consistently highlights the benefits of patient
navigation on CRC screening completion11,35–37 and
colon cancer care38,39. Finally, our program enhanced
communication between providers to facilitate CRC
screening efforts, receipt of screening results and
scheduling.
There are several strengths to our QI evaluation. Our
multi-modal intervention centers on a multi-disciplinary
approach to CRC screening; however, unlike other
interventions reported in the literature, our findings
highlight care coordination that includes GI specialists
through streamlined management of abnormal results
and coordinated scheduling efforts by our GI QI team.
The intervention conserved PCPs in their roles as the
primary liaison for patients, but aimed to offload PCPs by
enhancing communication lines and decreasing inter-
mediary steps. Second, we worked within a large, aca-
demic health care system with a diverse managed care
patient population. All patients had access to insurance
coverage with no out of pocket expense, which eliminated
patient concerns about the costs. Additionally, strong
financial incentives to stay within HMO insurance plans
promoted care within our system and facilitated accurate
collection of screening utilization data. Finally, we devel-
oped and engaged a multi-disciplinary QI team to provide
oversight for appropriate screening follow-up and to
optimize data capture and entry within the HM system.
Despite its strengths, our study is not without limita-
tions. First, we included the managed care population
from only one health care system, which may limit gen-
eralizability to other populations. However, this subgroup
had a low screening rate despite adequate insurance
coverage and an infrastructure to optimize screening
Fig. 3 Number of patients with a positive fecal immunochemical test (FIT)
who underwent diagnostic colonoscopy at 30 days, 60 days, 90 days,
180 days, 270 and 365 days. N (%)
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utilization. Thus, we felt that this patient population was
appropriate for our screening intervention. Second, many
of the processes in our intervention relied on manual data
entry and email communication for expedited procedure
scheduling, both of which require resources that may limit
the potential for intervention dissemination. Automation
of such processes within current EMRs might limit the
burden on health systems and increase intervention suc-
cess. Third, we were unable to account for screening tests
and colonoscopies performed outside of UCLA Health.
However, patient enrollment in a managed care plan
strongly dis-incentivizes out-of-network care. Our FIT
mailings also prompted participants to provide informa-
tion about screening completed at outside facilities, which
minimizes the opportunity for missed screening. Addi-
tionally, while we were able to exclude patients with a
documented history of CRC and/or total colectomy from
the cohort, we were unable to exclude patients considered
ineligible for screening due to high comorbidity. As a
result, some participants may not have been appropriate
for screening. Finally, because the study was completed as
a large multi-component intervention, it is impossible to
delineate the potential impact of individual components
on CRC screening uptake rate. Many health systems may
not be able to implement all components due to resource
and cost limitations; nonetheless, this intervention was
designed with the intention to synchronously address
multiple barriers to screening.
In conclusion, our work supports the use of multi-
modal interventions to increase CRC screening rates in an
academic-affiliated health system managed care popula-
tion. We also highlight the need for increased efforts to
improve colonoscopic follow-up after positive FIT. Given
that multiple patient, provider, and system barriers inhibit
successful population health management, health systems
should shift away from single-level interventions towards
interventions with multiple components to address the
multiple barriers to care delivery. With an increasing
focus on quality of care, comprehensive approaches like
these will help us achieve long-term control of CRC.
Future QI efforts should develop and evaluate such
interventions in other clinical settings, patient populations
and payment models. Additionally, future work should
determine and address barriers to diagnostic colonoscopy
among those with positive FIT results.
Study Highlights
What is current knowledge?
● Colorectal cancer (CRC) screening rates are below
the national goal of 80%.
● Single-component interventions aimed to improve
screening uptake only modestly improve CRC
screening rates.
What is new here?
● Interventions that target multiple patient-,
provider- and system-level barriers to CRC
screening effectively increase screening uptake.
● Rates of diagnostic colonoscopy after positive fecal
immunochemical test (FIT) are low and warrant
further investigation.
Translational impact
● Health systems should shift their focus from single-
level to multi-level interventions when addressing
barriers to CRC screening.
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